<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398720</url>
  </required_header>
  <id_info>
    <org_study_id>HTI-1066-101</org_study_id>
    <nct_id>NCT03398720</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Two-Part, Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with
      overexpression of c-Met. This 2-part, Phase 1 study evaluates the safety the tolerability of
      HTI-1066 in subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-part dose escalation and dose expansion study. Dose escalation uses a modified
      &quot;3+3&quot; design and continues until a maximum tolerated dose (MTD) or recommended phase 2 dose
      (RP2D) is identified. In part 2, subjects with selected tumor types will be enrolled at the
      MTD or RP2D.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 2 year</time_frame>
    <description>Number of participants with AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants with DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Peak concentration at Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies</measure>
    <time_frame>Up to 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One participant will receive HTI-1066 at the starting dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive HTI-1066 at dose level 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive HTI-1066 at dose level 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive HTI-1066 at dose level 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTI-1066 dose level 1</intervention_name>
    <description>Starting dose level</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTI-1066 dose level 2</intervention_name>
    <description>2nd dose level</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTI-1066 dose level 3</intervention_name>
    <description>3rd dose level</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTI-1066 dose level 4</intervention_name>
    <description>4th dose level</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥18 years of age

          2. Subject must have an advanced solid tumor

          3. ECOG Performance Status of 0 or 1

          4. Life expectancy ≥12 weeks

          5. Adequate laboratory parameters

          6. Female subjects agree not to be pregnant or lactating from beginning of the study
             screening until 4 months after receiving the last treatment; Male and female subjects
             and their sexual partners are willing and able to employ a highly effective method of
             birth control/contraception.

          7. Willing and able to comply with clinic visits and study-related procedures

          8. Provide signed informed consent

        Exclusion Criteria:

          1. Hypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody products

          2. Any concurrent therapy for cancer, radiation, or surgery within 4 weeks, except for
             minor palliative intent (this is to be discussed with sponsor)

          3. Any concurrent use of anti-infective, anti-fungal, or anti-viral agent (exceptions are
             to be approved by the sponsor)

          4. Any other prohibited or restricted medication as described in the study protocol.

          5. Investigational therapy administered &lt;5 half-lives before the first dose of HTI-1066

          6. Any anticancer therapy administered &lt;5 half-lives before first dose of HTI-1066; any
             prior immune-oncology products administered within 4 weeks or 5 half-lives before the
             first dose of HTI-1066 as described above; or surgery or radiotherapy administered
             within 4 weeks before the first dose of HTI-1066.

          7. Active CNS metastases.

          8. Cardiac disease (NYHA classes II-IV) including myocardial infarction within 6 months
             before enrollment, or unstable angina, congestive heart failure, or cardiac arrhythmia
             requiring treatment.

          9. History or presence of an abnormal ECG, ECHO, or MUGA that is clinically meaningful.

         10. History of immunodeficiency including seropositivity for human immunodeficiency virus
             (HIV), or other acquired or congenital immune-deficient disease, or any active
             systemic viral infection requiring therapy (e.g., hepatitis B or C)

         11. Any other medical, psychiatric, or social condition deemed by the investigator to be
             likely to interfere with a subject's rights, safety, welfare or ability to sign
             informed consent, cooperate and participate in the study, or interfere with the
             interpretation of the results

         12. Active infection or an unexplained fever &gt;38.5°C during Screening or on the first
             scheduled day of dosing.

         13. Unresolved toxicities from previous anticancer therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junsheng Wang, MD, PhD</last_name>
    <phone>+609 423 2155</phone>
    <phone_ext>205</phone_ext>
    <email>junsheng.wang@hengruitherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matt Cromie, MSc</last_name>
    <phone>+609 423 2155</phone>
    <phone_ext>219</phone_ext>
    <email>matt.cromie@hengruitherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Khemka, MD, MBA, FACP</last_name>
      <email>vivek.khemka@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Howard A Burris, MD</last_name>
      <email>howard.burris@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siqing Fu, MD</last_name>
      <phone>713-792-4318</phone>
      <email>siqingfu@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>January 6, 2018</last_update_submitted>
  <last_update_submitted_qc>January 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

